Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Application of Amniotic Membrane Allografts in Advanced Venous Leg Ulcer: A Case Study and Literature Review

Version 1 : Received: 31 August 2022 / Approved: 2 September 2022 / Online: 2 September 2022 (09:13:34 CEST)
Version 2 : Received: 2 September 2022 / Approved: 5 September 2022 / Online: 5 September 2022 (10:57:27 CEST)

How to cite: Lambert, N.; Vinke, E.; Barrett, T.; Regulski, M. Application of Amniotic Membrane Allografts in Advanced Venous Leg Ulcer: A Case Study and Literature Review. Preprints 2022, 2022090035. https://doi.org/10.20944/preprints202209.0035.v1 Lambert, N.; Vinke, E.; Barrett, T.; Regulski, M. Application of Amniotic Membrane Allografts in Advanced Venous Leg Ulcer: A Case Study and Literature Review. Preprints 2022, 2022090035. https://doi.org/10.20944/preprints202209.0035.v1

Abstract

Chronic venous insufficiency (CVI) is a lifelong, moribund, and debilitating disease process with tremendous personal and financial costs. At its core, CVI involves blood pooling in the lower extremities secondary to inadequate venous blood return, resulting in venous hypertension and incompetence of the one-way valves in the lower extremity veins. As venous circulation slows, metabolic demands of the cells in the lower extremities increase, leading to stasis dermatitis, infection, cellular death, and venous ulceration. This case study aims to report the efficacy of dehydrated amniotic membrane allograft (DAMA) applications to a chronic right lateral ankle ulcer resulting from chronic venous insufficiency. The patient in this study received DAMA applications weekly for six weeks. Upon examination at the initial application, the wound was wet and macerated due to drainage with significant hemosiderosis and lipodermatosclerosis consistent with a Venous Clinical Severity Score (VCSS) of 2. Upon inspection at the final visit, the wound was closed, with a VCSS of 0. This case study demonstrates that the application of DAMA has the potential to act as an effective barrier to cover and accelerate wound closure time. Future non randomized and randomized controlled trials may further establish standardized protocols for DAMA application in venous ulceration, help create treatment algorithms to predict wound closure endpoints, and encourage innovation that may further accelerate healing time.

Supplementary and Associated Material

http://regenativelabs.com: Company Website

Keywords

Chronic Venous Insufficiency; Venous Leg Ulcer; Dehydrated Amniotic Membrane Allograft

Subject

Biology and Life Sciences, Biology and Biotechnology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.